Artificial intelligence (AI) has established itself as a driving force in the life sciences industry. From drug development and clinical trials to logistics, approval and patient interaction: AI accelerates processes, enables new business models and increases operational efficiency. Today, the question is no longer whether AI delivers added value, but how companies can realign their structures and processes to realize the full potential of this technology.
The Intelligent life sciences report highlights how leading companies in the industry are driving change by adapting their operating models, breaking down silos and promoting AI-driven agility. The report also provides practical recommendations on how companies can develop a value-driven approach to AI to accelerate innovation, unlock new growth opportunities and maximize the return on their AI investments.
Meino Müller
Managing Partner, Head of Performance & Strategy
KPMG AG Wirtschaftsprüfungsgesellschaft
Key findings
About the "Intelligent life sciences" report
To shed light on the current state of AI integration and technology-related issues, KPMG International conducted a quantitative survey of 1,390 decision makers from eight industries (banking, retail, energy, healthcare, industrial manufacturing, life sciences, technology and insurance) in eight countries (Australia, Canada, China, France, Germany, Japan, the UK and the US). This cross-industry study involved 183 life sciences executives, 51 percent of whom were at C-suite level. They represent leading diagnostics companies as well as medium-sized pharmaceutical, biotech, medical technology and service companies in the pharmaceutical industry.
Intelligent life sciences report
The report shows how AI is changing the industry - and what companies need to do to create added value.
Download the study now